4//SEC Filing
TAYTON-MARTIN HELEN KATRINA 4
Accession 0001104659-20-005262
CIK 0001621227other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 9:35 PM ET
Size
8.7 KB
Accession
0001104659-20-005262
Insider Transaction Report
Form 4
TAYTON-MARTIN HELEN KATRINA
Chief Operating Officer
Transactions
- Award
Option to purchase Ordinary Shares
2020-01-16+1,257,744→ 1,257,744 totalExercise: $0.74Exp: 2030-01-16→ Ordinary Shares (1,257,744 underlying) - Award
Option to purchase Ordinary Shares
2020-01-16+280,896→ 280,896 totalExercise: $0.00Exp: 2030-01-16→ Ordinary Shares (280,896 underlying)
Footnotes (4)
- [F1]The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023, and 70,224 Ordinary Shares on January 16, 2024.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001661780
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 9:35 PM ET
- Size
- 8.7 KB